COR – Cencora, Inc.

Cencora, Inc. Monthly Stock Report – November 30, 2025

Company Overview

Cencora, Inc., headquartered in Conshohocken, Pennsylvania, operates at the forefront of the medical distribution industry within the healthcare sector. Established in 1871 and formerly known as AmerisourceBergen Corporation, Cencora has developed a comprehensive business model that focuses on sourcing and distributing pharmaceutical products across the globe.

The company’s U.S. Healthcare Solutions segment provides a wide array of products and services, including generic and injectable pharmaceuticals, over-the-counter healthcare items, and home healthcare supplies tailored for various healthcare organizations. This segment has positioned Cencora as a pivotal entity in fulfilling the ever-growing demand for medical supplies.

Additionally, Cencora’s International Healthcare Solutions segment specializes in pharmaceutical wholesale and logistics services, proving essential support to pharmacies, health centers, and hospitals worldwide. With increasing healthcare expenditures and an emphasis on efficient supply chain management following recent global health challenges, Cencora stands out as a compelling investment opportunity.

52-Week Price Performance Analysis

In analyzing the 52-week price performance of Cencora, Inc. (NASDAQ: COR), we observe a robust bullish trend, with the stock price appreciating approximately 48.79% over the past year. The stock currently trades at $369.93, showing a strong position well above its 52-week low of $223.92 and nearing its high of $377.54.

Technical Insights:

• Support Levels: The primary support level is situated around $250, which provided a solid foundation for price rebounds in the earlier months. The recent price action has established a new support level near $368.93.
• Resistance Levels: Resistance was once prominent around the $300 threshold, but the stock’s ability to breach this level indicates strong buying interest. Recent performance has led to the establishment of a new resistance level of approximately $368.93.
• Moving Averages: The stock consistently outperformed its moving averages, notably the 50-day moving average, currently at $332.58, suggesting ongoing bullish momentum. A breakout above the $368.93 level could signal a bullish continuation.

The price has formed a series of higher highs and higher lows over the past year, indicating a continuation of positive momentum. Currently, the pattern suggests a possible consolidation phase, an opportunity for investors to accumulate shares before the next potential upward movement.

Financial Performance and Metrics

Cencora’s financial metrics indicate a company in strong health, with total revenues reaching an impressive $321.33 billion. Here are the key financial highlights:

• Revenue: For Q3 2025, Cencora reported revenue of $80.7 billion, exceeding analyst expectations of $80.31 billion.
• Earnings: Adjusted earnings per share for the same quarter were $4, surpassing a forecast of $3.84.
• EBITDA: The company recorded an EBITDA of approximately $4.81 billion, showcasing solid operating profitability.
• Revenue Growth Forecast: The company has raised its 2026 adjusted earnings per share forecast to between $17.45 and $17.75, slightly above Wall Street expectations, driven largely by strong demand for specialty medicines.

Cencora has a total of 193,993,444 shares outstanding, with a low short interest of 0.0395% of its float, reflecting general confidence from investors regarding future growth and performance.

Recent News and Developments

Cencora is currently making headlines for its ambitious plans to invest over $1 billion in expanding its U.S. drug distribution network through 2030. This strategy includes the construction of:
– A 530,000-square-foot national distribution center in Harrison, Ohio, set to be operational by spring 2027.
– A 430,000-square-foot distribution facility in Fontana, California, projected to open by fall 2026.

These expansions aim to enhance domestic pharmaceutical manufacturing and mitigate reliance on foreign supply chains, addressing risks highlighted during recent global events.

Moreover, the company has successfully settled a stockholder derivative action for $111.3 million, related to oversight claims linked to controlled substances. Funded by insurance carriers, this settlement enables Cencora to strategically move forward without direct liability admission.

Investor confidence remains robust, as demonstrated by the stock reaching an all-time high of $351.55 on November 5, 2025, with a recorded year-to-date growth of 40.41%.

Market Sentiment and Analyst Recommendations

Cencora’s stock has garnered significant attention among analysts, reflected in a strong buy recommendation. The consensus from 14 analysts presents various price targets:
– Target High Price: $417.00
– Mean Price Target: approximately $384.79
– Median Target Price: $397.50
– Target Low Price: $300.00

With a mean recommendation rating of 1.75, the analysts maintain a positive sentiment about Cencora’s future performance, driven primarily by its strong revenue numbers, operational expansions, and proactive management of legal challenges.

Investment Opportunities and Risks

Investors in Cencora are presented with several opportunities, including:
– Continued growth in the medical distribution industry as healthcare expenditures rise.
– Strategic expansions that enhance operational capacity and production capabilities.

However, risks to consider include:
– Legal issues surrounding historical practices related to controlled substances.
– Potential market volatility due to changing regulations and global supply chain disruptions.

Conclusion

In summary, Cencora, Inc. represents a formidable investment opportunity within the healthcare sector, characterized by impressive revenue growth and a sturdy financial foundation. The stock’s performance reflects solid market confidence, backed by positive analyst recommendations and strategic initiatives aimed at bolstering its operational capabilities. As Cencora lays the groundwork for future growth, its position in the medical distribution industry is likely to strengthen, presenting a compelling case for investment amid a landscape of increasing healthcare demands.

Always conduct further research and consider your financial situation before making investment decisions.

Metric	Value
Market Cap	$71.8b
Total Debt	$9.3b
Total Cash	$4.4b
Shares Outstanding	194.0m
Float Shares	185.7m